• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome.

作者信息

Abu-Zeinah Ghaith, Di Giandomenico Silvana, Choi Daniel, Cruz Tatiana, Erdos Katie, Taylor Elwood, Ritchie Ellen K, Silver Richard T, Scandura Joseph M

出版信息

Blood Adv. 2022 Sep 27;6(18):5477-5481. doi: 10.1182/bloodadvances.2022007128.

DOI:10.1182/bloodadvances.2022007128
PMID:35789232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631704/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eec4/9631704/f7fa4b01fdb8/advancesADV2022007128f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eec4/9631704/55770a4f7bd7/advancesADV2022007128f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eec4/9631704/f7fa4b01fdb8/advancesADV2022007128f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eec4/9631704/55770a4f7bd7/advancesADV2022007128f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eec4/9631704/f7fa4b01fdb8/advancesADV2022007128f2.jpg

相似文献

1
Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome.JAK2V617F骨髓增殖性肿瘤的造血适应性与临床结果相关。
Blood Adv. 2022 Sep 27;6(18):5477-5481. doi: 10.1182/bloodadvances.2022007128.
2
Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.JAK2V617F 突变的骨髓增殖性肿瘤中的血栓形成。
Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):374-81. doi: 10.1177/1076029612453761. Epub 2012 Jul 23.
3
[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].[骨髓增殖性肿瘤中JAK2V617F突变的研究进展]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1329-33.
4
The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.JAK2V617F突变是JAK2V617F阳性骨髓增殖性肿瘤中特异性T细胞的靶点。
Leukemia. 2017 Feb;31(2):495-498. doi: 10.1038/leu.2016.290. Epub 2016 Oct 20.
5
The JAK2V617F mutation: no impact on circulating hematopoietic progenitors in myeloproliferative disorders.JAK2V617F突变：对骨髓增殖性疾病中循环造血祖细胞无影响。
Ann Hematol. 2008 Jun;87(6):509-11. doi: 10.1007/s00277-007-0428-x. Epub 2008 Jan 5.
6
TET2 loss, a rescue of JAK2V617F HSCs.TET2 缺失，拯救 JAK2V617F 造血干细胞。
Blood. 2015 Jan 8;125(2):212-3. doi: 10.1182/blood-2014-10-606624.
7
JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms.中国骨髓增殖性肿瘤患者的JAK2V617F等位基因负荷、JAK2 46/1单倍型及临床特征
Leukemia. 2013 Aug;27(8):1763-7. doi: 10.1038/leu.2013.21. Epub 2013 Jan 22.
8
JAK-2 mutations and their relevance to myeloproliferative disease.JAK-2突变及其与骨髓增殖性疾病的相关性。
Curr Opin Hematol. 2007 Jan;14(1):43-7. doi: 10.1097/00062752-200701000-00009.
9
[Quantification of JAK2V617F mutational burden in chronic myeloproliferative neoplasms].[慢性骨髓增殖性肿瘤中JAK2V617F突变负荷的定量分析]
Med Clin (Barc). 2012 Oct 13;139(9):393-4. doi: 10.1016/j.medcli.2012.04.018. Epub 2012 Jul 9.
10
JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.内脏静脉血栓形成中的JAK2V617F突变与骨髓增殖性疾病
Aliment Pharmacol Ther. 2011 Feb;33(4):495-6; author reply 496-7. doi: 10.1111/j.1365-2036.2010.04533.x.

引用本文的文献

1
Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis.仅使用鲁索替尼与联合使用干扰素治疗骨髓纤维化患者的疗效比较。
Blood Neoplasia. 2025 Mar 3;2(2):100082. doi: 10.1016/j.bneo.2025.100082. eCollection 2025 May.
2
Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms.HLA 基因型对骨髓增殖性肿瘤中突变 CALR 和 JAK2 V617F 驱动的肿瘤发生的差异调节。
Front Immunol. 2024 Sep 16;15:1427810. doi: 10.3389/fimmu.2024.1427810. eCollection 2024.
3
Are thrombosis, progression, and survival in ET predictable?

本文引用的文献

1
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.JAK2V617F 等位基因变异频率>50%可识别出患有静脉血栓形成高风险的真性红细胞增多症患者。
Blood Cancer J. 2021 Dec 11;11(12):199. doi: 10.1038/s41408-021-00581-6.
2
Normal life expectancy for polycythemia vera (PV) patients is possible.真性红细胞增多症（PV）患者有望实现正常预期寿命。
Leukemia. 2022 Feb;36(2):569-572. doi: 10.1038/s41375-021-01447-3. Epub 2021 Oct 8.
3
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival.
原发性血小板增多症中的血栓形成、病情进展及生存率是否可预测？
Blood Cancer J. 2024 Jun 25;14(1):103. doi: 10.1038/s41408-024-01079-7.
4
Identification of Novel Risk Variants of Inflammatory Factors Related to Myeloproliferative Neoplasm: A Bidirectional Mendelian Randomization Study.骨髓增殖性肿瘤相关炎症因子新风险变异体的鉴定：一项双向孟德尔随机化研究
Glob Med Genet. 2024 Feb 12;11(1):48-58. doi: 10.1055/s-0044-1779665. eCollection 2024 Jan.
5
Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms.用于早期检测费城阴性骨髓增殖性肿瘤的分子研究。
Int J Mol Sci. 2023 Aug 11;24(16):12700. doi: 10.3390/ijms241612700.
6
JAK2 V617F allele burden in polycythemia vera: burden of proof.真性红细胞增多症中 JAK2 V617F 等位基因负担：证据负担。
Blood. 2023 Apr 20;141(16):1934-1942. doi: 10.1182/blood.2022017697.
α干扰素治疗真性红细胞增多症可改善无骨髓纤维化生存期和总生存期。
Leukemia. 2021 Sep;35(9):2592-2601. doi: 10.1038/s41375-021-01183-8. Epub 2021 Mar 2.
4
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.重建骨髓增殖性肿瘤中单个癌细胞的谱系历史和分化轨迹。
Cell Stem Cell. 2021 Mar 4;28(3):514-523.e9. doi: 10.1016/j.stem.2021.02.001. Epub 2021 Feb 22.
5
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.骨髓增殖性肿瘤的分类与个体化预后
N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.
6
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.费城染色体阴性经典骨髓增殖性肿瘤：欧洲白血病网的修订管理建议。
Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.
7
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.评估骨髓形态对于评估重组干扰素α治疗的真性红细胞增多症患者的疾病状态至关重要。
Haematologica. 2017 Mar;102(3):e97-e99. doi: 10.3324/haematol.2016.153973. Epub 2016 Nov 3.
8
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
9
Effect of mutation order on myeloproliferative neoplasms.突变顺序对骨髓增殖性肿瘤的影响。
N Engl J Med. 2015 Feb 12;372(7):601-612. doi: 10.1056/NEJMoa1412098.
10
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.分子注释的原发性血小板增多症、真性红细胞增多症和骨髓纤维化的长期生存及原始细胞转化
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18.